EBITDA Margin % is calculated as EBITDA divided by its Revenue. Histogen's EBITDA for the
three
months ended in Sep. 2023 was $-3.83 Mil. Histogen's Revenue for the
three
months ended in Sep. 2023 was $0.01 Mil. Therefore, Histogen's EBITDA margin for the quarter that ended in Sep. 2023 was -76,600.00%.
Histogen EBITDA Margin % Historical Data
The historical data trend for Histogen's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Histogen's EBITDA Margin %
For the Biotechnology subindustry, Histogen's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Histogen's EBITDA Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Histogen's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Histogen's EBITDA Margin % falls into.
Histogen EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Histogen's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Histogen (OTCPK:HSTO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Histogen EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Histogen's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HSTO has been successfully added to your 